Sandy Allerheiligen, PhD joined Certara in 2017 and was named Senior Vice President of Strategic Consulting, Health Economics, and Education. Her recent work has focused on using her predictive, economic, and model-informed drug development expertise to quantify a drug’s value to patients and justify its cost to payers. Prior to joining Certara, she held positions at Merck (Vice President of Modeling and Simulation, Vice President of Quantitative Pharmacology and Pharmacometrics, and Vice President of Predictive and Economic Modeling). In addition to Merck, Dr. Allerheiligen worked at Lilly for 20 years in PKPD and retired as Distinguished Fellow and Chief Scientific Officer of Quantitative Pharmacology.
Dr. Allerheiligen received her doctorate in Pharmaceutics from the University of Texas, Austin. She completed her postdoctoral fellowship in Gastroenterology and served as a clinical assistant professor of Clinical Pharmacology at The University of Texas Health Science Center at San Antonio.
Through her involvement in American Association of Pharmaceutical Scientists, American Association of Clinical Pharmacology and Therapeutics, International Society of Pharmacometrics, and NIH Working Groups, she has worked to expand the use of modeling and simulation, and quantitative and systems pharmacology methodologies, in academia, regulatory agencies, and across the industry. She is an international speaker on modeling and simulation topics. Dr. Allerheiligen is a Fellow of both the American Association of Pharmaceutical Sciences and the American College of Clinical Pharmacology. In 2016, she received the International Society of Pharmacometrics Leadership Award.